Here is why Vodafone Idea and Indus Towers shares are selling off on Wednesday

Shares of Vodafone Idea Ltd. and Indus Towers Ltd. are among the worst performing stocks on the Nifty 500 index on Wednesday, March 12. While shares of Indus Towers are down 7%, those of Vodafone Idea are down 6%.

Recent developments saw peers of Vodafone Idea, Jio Platforms and Bharti Airtel announcing tie-ups with Elon Musk’s SpaceX to bring Starlink services to India.

In response, shares of Reliance Industries are continuing their rebound from their recent lows. Bharti Airtel shares had opened higher but have now turned negative.

Starlink is an advanced internet systems that enables video and internet services at the most remote locations. Starlink uses Low-Earth Orbit satellite network to provide internet access to its users. This is different from traditional networks that either rely on towers or underground cables for network.

Additionally, based on the recently released telecom data, Vodafone Idea’s subscriber base narrowed by another 1.71 million users during the month of December to 207.25 million. This was higher than the 1.5 million subscribers it lost in November.

Vodafone Idea’s market share also fell to 18.01% from 18.19% earlier.

Last month, brokerage firm Motilal Oswal had written in a note that the stabilisation of subscriber losses is the single-most important factor for Vodafone Idea’s survival over the long-term.

Vodafone Idea is embarking on a significant capex cycle over the next two to three years to bridge the network gap with peers. “However, we believe that Vodafone Idea’s capex plans are contingent on a debt raise and further relief from the government,” Motilal Oswal said in its note.

Out of the 21 analysts covering Vodafone Idea, 12 of them have a “sell” rating on the stock, while four have a “buy” recommendation. The rest, say “hold.”

For Indus Towers, 13 out of the 24 analysts have a “buy” rating on the stock, while five have a “sell” rating.

Shares of Vodafone Idea are now below the mark of ₹7 after Wednesday’s 6% fall. The stock is now down 64% from its 2024 peak.

Shares of Indus Towers are down 6.7% at ₹318.45. The stock is down 31% from its recent peak of ₹460.

Eqwires Research Analyst

Top-notch SEBI registered research analyst

Best SEBI registered Intraday tips provider

info@eqwires.com

Telegram Facebook Instagram

Call: +91 9624421555 / +91 9624461555

www.eqwires.com

Ola Electric to begin motorcycle deliveries soon, says CFO Harish Abichandani

Ola Electric Mobility is set to begin delivering its motorcycles by the end of this month or early April, according to Harish Abichandani, CFO of Ola Electric.

Abichandani said the company is on track to significantly expand its product portfolio, and market share will be a result of continued expansion in distribution and product availability.

“We have reported a market share of 28% for February. We continue to see strong momentum going into March, and with new products, this will only get better in the new financial year,” he said.

The company has completed the implementation of its network transformation and operating expense (OpEx) reduction programme, resulting in a cost reduction of ₹90 crore per month. The full financial impact of these initiatives will be reflected in April 2025.

Abichandani also stated that Ola Electric’s new initiatives have reduced average vehicle inventory to 20 days from 35 days, while customer delivery time has come down from 12 days to 3-4 days. He emphasised that further improvements are expected as the company continues refining its distribution network.

On profitability, he said that while earnings before interest, taxes, depreciation and amortisation (EBITDA) break-even was initially tied to reaching 50,000 monthly deliveries, stronger-than-expected cost efficiencies could accelerate profitability. “We have actually done significantly more on cost than even envisaged and planned, and the goalpost could shift positively towards profitability much earlier,” he said.

Ola Electric remains focused on improving operational efficiencies and expanding its product lineup, including upcoming motorcycles. The company is committed to achieving profitability in the April-June quarter of 2025 (Q1FY26). “Path to profitability is something we will deliver by Q1 of FY26,” he stated.

The market capitalisation of Ola Electric Mobility is around ₹22,671.67 crore. Its shares have declined close to 55% in the past six months.

Eqwires Research Analyst

Top-notch SEBI registered research analyst

Best SEBI registered Intraday tips provider

info@eqwires.com

Telegram Facebook Instagram

Call: +91 9624421555 / +91 9624461555

www.eqwires.com

Alkem Laboratories launches generic empagliflozin in India

Under brand name ‘Empanorm’

Alkem Laboratories announced the launch of generic empagliflozin and its combinations in India under the brand name Empanorm at prices that are approximately 80% lower than the innovator products.

Empagliflozin is an SGLT-2 (Sodium-Glucose Co-Transporter-2) inhibitor indicted for use in the treatment of type-2 diabetes mellitus, chronic kidney disease (CKD) and chronic heart failure (HF). Alkem’s generic empagliflozin and its combinations are bioequivalent to innovator products.

With a patient-centric approach, Alkem has introduced anti-counterfeit security band on the pack of Empanorm, as well as comprehensive patient education information, including basic details on diabetes management in Hindi and English with infographics, and QR codes that provide prescribing information and additional patient education information on diabetes, heart failure, and chronic kidney disease in 11 languages.

Keeping patient-convenience in mind, Alkem is offering the medicine in a considerably smaller tablet size than the innovator products.

Alkem’s generic empagliflozin is available under the brand name Empanorm and its combinations namely: (i) empagliflozin and linagliptin is available under the name Empanorm L; (ii) empagliflozin and sitagliptin is available under the name Empanorm Duo and Alsita E; and (iii) empagliflozin and metformin is available under the name Empanorm M.

Eqwires Research Analyst

Top-notch SEBI registered research analyst

Best SEBI registered Intraday tips provider

info@eqwires.com

Telegram Facebook Instagram

Call: +91 9624421555 / +91 9624461555

www.eqwires.com